Search results for "Curocell"

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

Curocell announced on Sept. 4 that its chimeric antigen receptor T-cell (CAR-T) therapy Rimqarto (generic name: anbalcabtagene autoleucel) was deemed...
Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood

Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T) therapies, announced on June 15 that...
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...
Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone

Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone

For patients with aggressive blood cancers that recur or fail to respond to standard chemotherapy, chimeric antigen...